<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a group of progressive, clonal, neoplastic <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow disorders</z:e> characterized by hematopoietic stem cell dysregulation and abnormalities in the immune system </plain></SENT>
<SENT sid="1" pm="."><plain>Mesenchymal stem cells (MSC) have gained further interests after the demonstration of an immunoregulatory role </plain></SENT>
<SENT sid="2" pm="."><plain>Nevertheless, the immunoregulatory function of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> bone marrow derived MSC (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MSC) remains poorly defined </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, it is not clear whether there are differences in the regulatory functions between low-risk and high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MSC </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, we obtain and expand MSC from bone marrow of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Our results show that there are significant differences in the immunoregulatory functions between low-risk and high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MSC </plain></SENT>
<SENT sid="6" pm="."><plain>Compare to low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MSC, high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MSC is associated with the presence of increased TGF-β1, higher <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, higher immunosuppressive rate and a poor ability of hematopoietic support </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, our results find that there are great differences in the CD4+CD25+Foxp3+Tregs inducible rate between high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MSC and low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MSC </plain></SENT>
<SENT sid="8" pm="."><plain>Compared to high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MSC, the inducible rate of CD4+CD25+Foxp3+Tregs of low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MSC is lower </plain></SENT>
<SENT sid="9" pm="."><plain>At last, we find that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-MSC derived TGF-β1 is largely responsible for the increase in CD4+CD25+Foxp3+Tregs based on knockdown studies </plain></SENT>
<SENT sid="10" pm="."><plain>These results elucidate the different immunoregulatory role of MSC in low-risk and high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, which may be important for understand the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and the development of novel immunomodulatory strategies for the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>